首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1341篇
  免费   98篇
  国内免费   8篇
耳鼻咽喉   4篇
儿科学   58篇
妇产科学   19篇
基础医学   146篇
口腔科学   29篇
临床医学   201篇
内科学   267篇
皮肤病学   16篇
神经病学   81篇
特种医学   266篇
外科学   126篇
综合类   22篇
一般理论   1篇
预防医学   53篇
眼科学   16篇
药学   47篇
中国医学   6篇
肿瘤学   89篇
  2024年   3篇
  2023年   9篇
  2022年   4篇
  2021年   21篇
  2020年   13篇
  2019年   13篇
  2018年   33篇
  2017年   23篇
  2016年   22篇
  2015年   30篇
  2014年   41篇
  2013年   37篇
  2012年   49篇
  2011年   37篇
  2010年   48篇
  2009年   73篇
  2008年   48篇
  2007年   30篇
  2006年   30篇
  2005年   22篇
  2004年   25篇
  2003年   28篇
  2002年   36篇
  2001年   20篇
  2000年   18篇
  1999年   17篇
  1998年   56篇
  1997年   52篇
  1996年   67篇
  1995年   51篇
  1994年   44篇
  1993年   48篇
  1992年   26篇
  1991年   18篇
  1990年   30篇
  1989年   48篇
  1988年   39篇
  1987年   42篇
  1986年   39篇
  1985年   25篇
  1984年   17篇
  1983年   14篇
  1982年   23篇
  1981年   14篇
  1980年   9篇
  1978年   7篇
  1977年   13篇
  1976年   11篇
  1975年   13篇
  1965年   3篇
排序方式: 共有1447条查询结果,搜索用时 15 毫秒
1.
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma.  相似文献   
2.
3.
A case of primary non-Hodgkin's lymphoma (NHL) of the mandible with unusual radiographic presentation is reported. The panoramic radiography revealed diffuse widening of the right mandibular canal with ill-defined margins and absence of edge sclerosis. Computed tomography showed infiltration of the superior portion of the canal with involvement of the vestibular cortex of the bone and of the alveolar ridge. Correspondence to: M. Bertolotto  相似文献   
4.
5.
6.
7.
8.
9.
S Ciatto  S Cecchini  A Isu  A Maggi  S Cammelli 《Tumori》1992,78(1):22-25
The characteristics associated with non-attendance to mammographic breast cancer screening were studied by interviewing a random sample (213 attenders, 121 non-attenders in the 1989 screening) of residents in one of the municipalities of the Florence District Program, where screening has been ongoing since 1970. The overall attendance rate was 60%, and it was dependent on age (40-49 years, 66.5%; 50-59 years, 62.5%; 60-70 years, 55.5%), whereas a significant association with socio-economic status, educational level and health-behavior reported in other programs was not confirmed in the study. This finding suggests that determinants of non-attendance may vary and should be evaluated in each local setting. The belief that screening is useless, fear of cancer being detected, postponement and laziness were the most common motivations of refusal stated by non-attenders, and such a negative attitude towards screening was rather strong since most non-attenders stated they would not like to be informed or stimulated to attend future screenings. Rapid improvement of attendance rates in such a context might be achieved only by putting special pressure on women aimed to change their negative attitude towards screening and their opinion about the benefits of early breast cancer detection. This might be regarded as unacceptable and however would involve high costs and a major organization effort.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号